Lenalidomide

• Catalog No.: Bio-0168
• CAS Number: 191732-72-6
• M. F.: C13H13N3O3
• M. W.: 259.26062

SYNONYMS

• IUPAC name: 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
• IUPAC Traditional name: 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
• Synonyms: Revimid; Revlimid

DATABASE IDS

• CAS Number: 191732-72-6

PROPERTIES

• Application(s): Used against multiple myeloma and myelodysplastic syndromes
• Mechanism of Action: Interfering with the immune system and angiogenesis
• Mechanism of Action: Inhibits the expression of cyclooxygenase-2 (COX-2)

REFERENCES

• Bennett et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer JAMA 2006;296(21):2558-2560
• List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57. PMID 15703420.
• Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Numer SD, Jagannath S, Dhodapkar MV.
• Enhancement of ligand dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;epub ahead of print. PMID 16569772.
• Anderson KC. Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol 2005;42(4 Suppl 4):S3-8. PMID 16344099.
• Armoiry, X et al. Lenalidomide in the treatment of multiple myeloma: a review J of Clin Pharmacy & Therapeutics 2008;33:219-226
• Vellet, S et al Thalidomide and lenalidomide: mechanism-based potential drug combinations Leukemia and Lymphoma 2008;49(7):1238-1245
• Weber, DM et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America N Engl Med 2007;357(21):2133-2142